Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program

2013 ◽  
Vol 92 (7) ◽  
pp. 830-840 ◽  
Author(s):  
Ellinor Östensson ◽  
Ann-Cathrin Hellström ◽  
Kristina Hellman ◽  
Inger Gustavsson ◽  
Ulf Gyllensten ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Screening Program ◽  
Human Papillomavirus Testing ◽  
Cancer Screening Program ◽  
Cervical Cancer Screening Program

scholarly journals Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Julio Cesar Teixeira ◽  
Diama Bhadra Vale ◽  
Joana Froes Bragança ◽  
Cirbia Silva Campos ◽  
Michelle Garcia Discacciati ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Screening Program ◽  
Effectiveness Study ◽  
Hpv Testing ◽  
Cancer Screening Program ◽  
Cervical Cancer Screening Program ◽  
Cost Effectiveness Study

PP62 Cost-Effectiveness Of Cervical Cancer Screening In Estonia

2019 ◽  
Vol 35 (S1) ◽  
pp. 49-49
Author(s):  
Triin Võrno ◽  
Kaja-Triin Laisaar ◽  
Terje Raud ◽  
Kai Jõers ◽  
Doris Meigas-Tohver ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Screening Program ◽  
Pap Test ◽  
Cancer Screening Program ◽  
Hpv Test ◽  
Cervical Cancer Screening Program ◽  
The Cost

IntroductionIn Estonia, organized cervical cancer screening program is targeted at women aged 30–55(59) years and Pap-tests are taken every five years. Since cervical cancer is associated with human papillomavirus (HPV), a number of countries have introduced the HPV-test as the primary method of screening. The objective of this study was to evaluate the cost-effectiveness of organized cervical cancer screening program in Estonia by comparing HPV- and Pap-test based strategies.MethodsFor the cost-effectiveness analysis, a Markov cohort model was developed. The model was used to estimate costs and quality-adjusted life-years (QALYs) of eight screening strategies, varying the primary screening test and triage scenarios, upper age limit of screening, and testing interval. Incremental cost-effectiveness ratios (ICERs) were calculated in comparison to current screening practice as well as to the next best option. Sensitivity analysis was performed by varying one or more similar parameter(s) at a time, while holding others at their base case value. The analysis was performed from the healthcare payer perspective adopting a five percent annual discount rate for both costs and utilities.ResultsIn the base-case scenario, ICER for HPV-test based strategies in comparison to the current screening practice was estimated at EUR 8,596–9,786 per QALY. For alternative Pap-test based strategies ICER was estimated at EUR 2,332–2,425 per QALY. In comparison to the next best option, HPV-test based strategies were dominated by Pap-test based strategies. At the cost-effectiveness threshold of EUR 10,000 per QALY Pap-testing every three years would be the cost-effective strategy for women participating in the screening program from age 30 to 63 (ICER being EUR 3,112 per QALY).ConclusionsDecreasing Pap-test based screening interval or changing to HPV-test based screening can both improve the effectiveness of cervical cancer screening program in Estonia, but based on the current cost-effectiveness study Pap-test based screening every three years should be preferred.

scholarly journals Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Priscilla Brebi ◽  
Carmen Gloria Ili ◽  
Alejandra Andana ◽  
Doris Menzel ◽  
Jaime Lopez ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Screening Program ◽  
Cancer Screening Program ◽  
Cervical Cancer Screening Program

scholarly journals Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in Québec, Canada

2010 ◽  
Vol 101 (3) ◽  
pp. 220-225 ◽  
Author(s):  
Arthi Vijayaraghavan ◽  
Molly B. Efrusy ◽  
Marie-Hélène Mayrand ◽  
Christopher C. Santas ◽  
Patricia Goggin
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Human Papillomavirus Testing
Sign in / Sign up

Export Citation Format

Share Document